TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04078269

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cell immunotherapy
Description: Intravenous infusions of MIDRIXNEO-LUNG DCs every 2 weeks, using an intra-patient dose escalation scheme progressing along the following range: 10 x10E6 DCs (minimal dose), 20 x 10E6 DCs, 40 x 10E6 DCs, 80 x 10E6 DCs, 100 x 10E6 DCs (maximal dose), until exhaustion of the batch or occurrence of grade ≥3 toxicity event

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antigen-specific DTH
Description: Intradermal injection of 1 x 10E6 MIDRIXNEO-LUNG DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of induction of antigen-specific immune responses as part of in vivo immunomonitoring (delayed-type hypersensitivity cutaneous reaction as test read-out)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Control DTH
Description: Intradermal injection of 1 x 10E6 MIDRIX-CTRL DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of background (i.e. non-antigen-specific) reactivity (delayed-type hypersensitivity cutaneous reaction as test read-out)
Study: NCT02031003

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Infant formula
Description: Infant formula

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Infant formula
Description: Infant formula

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Infant formula
Description: Infant formula
Study: NCT01063348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetyl Cysteine
Description: Week 0 (Visit 1) - Week 3 (V2): 1200mg/day (600mg po qam and 600mg po qpm) Week 3 (V2) - Week 6 (V3): 2400mg/day (1200mg po qam and 1200mg po qpm) Week 6 (V4) - Week 12 (V5): 3000mg/day (1200mg po qam and 1800mg po qpm)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules taken in same amount of pills as the active medication.
Study: NCT03845829

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In situ laser assisted fenestration
Description: In situ laser assisted fenestration for the left subclavian artery during the procedure of TEVAR for type B aortic dissection
Study: NCT02651116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan Hydrobromide
Description: 15 mg/ 10 mL: 10 mL of Dextromethorphan Hydrobromide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mL Placebo

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cough recording device
Description: FDA approved device validated for use in adults and children

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cough recording device
Description: FDA approved device validated for use in adults and children
Study: NCT02885103

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal high flow (NHF)
Description: NHF will be combinated with a nebulizer. Inhalation will be done on nasal cavity.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nebulizer
Description: Inhalation will be done will Nebulizer and via mouth
Study: NCT00358852

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study. The data will be collected of patients suffering from schizophrenia and schizoaffective disorder / schizophreniform.
Study: NCT02701400

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Given IV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study: NCT01621854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-1031
Description: Cohort 1, Schedule A, NUC-1031 I.V. 1000mg/m2, Days 1, 8, \& 15 every 28 days Cohort 1, Schedule B, NUC-1031 I.V. 500mg/m2, Days 1 \& 5, 8 \& 12, 15 \&19 every 28 days Cohort 2, Schedule A, NUC-1031 I.V. 2000mg/m2, Days 1, 8, \& 15 every 28 days Cohort 2, Schedule B, NUC-1031 I.V. 1000mg/m2, Days 1 \& 5, 8 \& 12, 15 \&19 every 28 days
Study: NCT05918588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil mesylate
Description: Pharmaceutical form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil mesylate
Description: Pharmaceutical form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil mesylate
Description: Pharmaceutical form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil mesylate
Description: Pharmaceutical form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: capsule; Route of administration: oral
Study: NCT02524756

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic nerve-sparing radical hysterectomy-type III/C1

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic radical hysterectomy (type III/C2).
Study: NCT03373110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Mindfulness Based Cognitive Therapy
Description: see arm description

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Cognitive Behavioral Therapy
Description: see arm description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Alone
Description: see arm description
Study: NCT05883007

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerator-based BNCT with borofalan(10B)
Description: Patients will be treated with BNCT regulated as 12, 15, or 18 Gy-Eq of the mucosal maximum dose.
Study: NCT00730626

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt with 1X10E9 BB-12 and LA-5
Description: 100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E9 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt with 1X10E10 BB-12 and LA-5
Description: 100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E10 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Yogurt Placebo
Description: 100g of yogurt placebo containing no probiotics and no green tea extract, once a day for 10 weeks.
Study: NCT05349942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoral scanning and data acquisition
Description: Intraoral scanner data acquisition, 3 scans are taken for each participant. Data will be exported from dedicated software (Planmeca, Romexis) and imported into GOM surface analysis software. Sample comparisons and sample preparation are performed here. The results are collected in excel spreadsheets and analyzed in SPSS statistical software.
Study: NCT00676208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared Medical Appointments
Description: Participated in shared appointments for patients as part of interprofessional team providing care for diabetes
Study: NCT03783338

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Aerobic exercises and Vitamin D supplementation
Description: Aerobic exercises:~Children in groups B and C will receive aerobic exercises in the form of bicycle ergometer and treadmill training for 15 min 3 days/week for 12 weeks. The procedure and goals of exercise will be explained to all children before starting the exercise program. The child will stop exercising immediately if he feels pain, fainting or shortness of breath.~Vitamin D supplementation:~Children in group C only will receive vitamin D supplementation in the form of an oral daily dose of vitamin D3 1000 IU (Cholecalciferol) for 12 weeks.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercises and Vitamin D supplementation
Description: Aerobic exercises:~Children in groups B and C will receive aerobic exercises in the form of bicycle ergometer and treadmill training for 15 min 3 days/week for 12 weeks. The procedure and goals of exercise will be explained to all children before starting the exercise program. The child will stop exercising immediately if he feels pain, fainting or shortness of breath.~Vitamin D supplementation:~Children in group C only will receive vitamin D supplementation in the form of an oral daily dose of vitamin D3 1000 IU (Cholecalciferol) for 12 weeks.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Aerobic exercises and Vitamin D supplementation
Description: Aerobic exercises:~Children in groups B and C will receive aerobic exercises in the form of bicycle ergometer and treadmill training for 15 min 3 days/week for 12 weeks. The procedure and goals of exercise will be explained to all children before starting the exercise program. The child will stop exercising immediately if he feels pain, fainting or shortness of breath.~Vitamin D supplementation:~Children in group C only will receive vitamin D supplementation in the form of an oral daily dose of vitamin D3 1000 IU (Cholecalciferol) for 12 weeks.
Study: NCT01930929

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Study: NCT04239547

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar Recruitment maneuver (ARM) +PEEP
Description: Following anesthesia induction and intubation, alveolar recruitment maneuver followed by 5 mmHg PEEP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP
Description: Following anesthesia induction and intubation, only 5 mmHg PEEP
Study: NCT03921047

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04294095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: My Baby My Move +
Description: This is a community-based, peer-led 12-week wellness intervention to decrease excessive gestational weight gain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: This is a 12-week basic prenatal education class.
Study: NCT02826993

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CCE in incomplete Colonoscopies
Description: When the initial colonoscopy has failed, participants are invited to ingest a CCE on the day prior to their subsequent CT colonography. Thus, the CCE and CT will be compared within subjects for their ability to identify and estimate sizes of polyps
Study: NCT01273493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin 0.58 or 1.3 mg/m\^2 (or adjusted dose) i.v. will be administered on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin 0.58 or 1.3 mg/m\^2 (or adjusted dose) i.v. will be administered on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered as 20 mg/m\^2, 30 minutes prior to trabectedin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered as 20 mg/m\^2, 30 minutes prior to trabectedin.
Study: NCT01847612

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: indocyanine green fluorescent cholangiography

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylene blue
Study: NCT00067613

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Benchmarking Management Practices
Description: The Benchmarking intervention included:~1. Data feedback: Using existing data from the NRN Generic Database and Key Care Practices Survey at their NICU to collect data on the perceptions of care.~2. Training in Continuous Quality Improvement (CQI) Techniques~3. Review of best existing evidence~4. Site visits to the Centers with the Lowest Rates of BPD~5. Selection of Practices to change: Each site team selected practices for modification at their own center

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Management Practices
Description: Centers assigned to the control group continued to receive routine information on their own center's outcomes, and all information routinely supplied within the NRN. Control centers did not participate in organized discussions of the interventions applied within the Benchmarking centers. At the completion of the study, Control Centers were offered a workshop on the Benchmarking techniques.
Study: NCT02667457

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 99mTc-rhAnnexin V-128

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 99mTc-rhAnnexin V-128
Study: NCT03162458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaferon for children (liquid dosage form)
Description: 10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.
Study: NCT00707772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)
Description: PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: 800 milligram per day (PO)
Study: NCT04102852

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG ATCC 53103
Description: probiotic administration at two different doses for 1 month

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG ATCC 53103
Description: probiotic administration at two different doses for 1 month
Study: NCT01923623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine block

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine block
Study: NCT03056820

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 25° head-up position
Description: Participant will be positioned at 25° angle for procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 55° head-up position
Description: Participant will be positioned at 55° angle for procedure.
Study: NCT02800213

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Ambu Spur II bag valve mask
Description: Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a modified Ambu Spur II bag valve mask with a supplemental external handle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Ambu Spur II bag valve mask
Description: Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a modified Ambu Spur II bag valve mask with a supplemental external handle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Ambu Spur II bag valve mask
Description: Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a conventional Ambu Spur II bag valve mask

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional Ambu Spur II bag valve mask
Description: Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a conventional Ambu Spur II bag valve mask
Study: NCT02876575

Intervention type: DEVICE
Group type: OTHER
Intervention: A bipolar instrument for tonsillectomies
Description: A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
Study: NCT03265366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany), without injection or inhalation of contrast agent.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany), without injection or inhalation of contrast agent.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT scan (standard reference)
Description: It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CT scan (standard reference)
Description: It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.
Study: NCT04336514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Semi-compressed felt pad (SCF)
Description: Participants with forefoot callus will receive routine treatment of debridement of callus. Along with the debridement, a Plantar Metatarsal Pad (PMP) made of Semi-Compressed Felt (SCF) with appropriate cut outs will be placed in their shoes. The thickness of the SCF would be selected based on the patient weight, and appropriateness of the thickness would be confirmed by the Medilogic pressure measurement. A 50% pressure reduction is the desired outcome.
Study: NCT03162458

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (liquid dosage form)
Description: 10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.
Study: NCT01726283

Intervention type: DEVICE
Intervention: Corneal Cross-Linking
Description: Corneal cross-linking procedure conducted during vision correction surgery.

Intervention type: DEVICE
Intervention: Corneal Cross-Linking
Description: Corneal cross-linking procedure conducted during vision correction surgery.

Intervention type: DRUG
Intervention: Riboflavin
Description: Riboflavin will be instilled prior to corneal cross linking.

Intervention type: DRUG
Intervention: Riboflavin
Description: Riboflavin will be instilled prior to corneal cross linking.
Study: NCT03474432

Intervention type: DEVICE
Group type: OTHER
Intervention: Optical Coherence Tomography
Description: OCT will be performed with the St. Jude OCT system. Detection of metallic stent struts will be performed automatically with manual adjustments made as necessary. Stent area tracings will be automatically performed by interpolated contours connecting the center point of the luminal surface of each detected metallic strut. Stent expansion will be determined as the minimum stent area divided by the average reference lumen area and presented as a percentage. Neo-intimal hyperplasia (NIH) area will be determined in follow-up examinations as the area between the stent and lumen contours. Incomplete stent apposition (ISA) area will be determined as the area between the stent contour and the lumen contour at the site of malapposed struts, in a region not overlying a side branch ostium.
Study: NCT00672165

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195
Description: A single infusion of 225Ac-HuM195 will be administered at a starting dose of 0.5 μCi/kg. Additionally, 100 mCi of 213Bi-HuM195 have been administered with full dose cytarabine (200 mg/m2 daily for 5 days) without dose-limiting toxicity.Serial sampling of blood, urine, and bone marrow will be performed following treatment to determine the toxicity, pharmacokinetics, immunogenicity, and antileukemic effects. Three to six patients will be treated at each dose level. Dose escalation will proceed if less than 33% of patients in a cohort experience dose-limiting toxicity.Patients will be followed until completion of therapy as outlined in the study, loss to follow-up, death, or until the day the patient is removed from the study.
Study: NCT01064141

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: OKAVAX®:Attenuated live varicella-zoster virus and AVAXIM® 80U: Hepatitis A virus Vaccines
Description: 0.5 mL, Subcutaneous and 0.5 mL, Intravascular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and Childhood vaccines
Description: 0.5 mL, Subcutaneous and 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and NaCl (Placebo)
Description: 0.5 mL Subcutaneous and 0.5 mL Subcutaneous
Study: NCT03332927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg based breakfast foods
Description: Two eggs/day, 6 days per week provided as breakfast foods such as burrito-type roll-up, egg sandwich and omelet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-egg based breakfast foods
Description: Non-egg based control foods provided as breakfast foods 6 days per week such as waffles, ready-to-eat cereal, fruits and cheeses.
Study: NCT03577262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C]-UCB-J
Description: IV radioligand given prior to and during positron emission tomography (PET) scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C]-UCB-J
Description: IV radioligand given prior to and during positron emission tomography (PET) scan
Study: NCT00173875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iressa
Study: NCT04648566

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine administration of hCG-activated peripheral blood mononuclear cells
Description: Administration of hCG-activated peripheral blood mononuclear cells in the uterine cavity of the patient

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine administration of hCG-activated peripheral blood mononuclear cells
Description: Administration of hCG-activated peripheral blood mononuclear cells in the uterine cavity of the patient

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine administration of hCG-activated peripheral blood mononuclear cells
Description: Administration of hCG-activated peripheral blood mononuclear cells in the uterine cavity of the patient

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intrauterine administration of sperm washing medium
Description: Administration of sperm washing medium instead of PBMC in the uterine cavity of the patient
Study: NCT00707772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)
Description: PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: \[=\<75 kg: 1000 mg; \>75 kg: 1200 mg per day (PO)\]